4 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Angela Holmes of Mercury Data Science, Meredith Wheeler and Maggie Segrich of Sesh Coworking, and Shaun Zhang of the University of Houston. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from data science to cancer therapeutics — recently making headlines in Houston innovation.

Angela Holmes, CEO of Mercury Data Science

Angela Holmes is the CEO of MDS. Photo via mercuryds.com

A Houston-based AI solutions consultancy has made changes to its C-suite. Dan Watkins is passing on the CEO baton to Angela Holmes, who has served on MDS's board and as COO. As Holmes moves into the top leadership position, Watkins will transition to chief strategy officer and maintain his role on the board of directors.

"It is an exciting time to lead Mercury Data Science as we advance the development of innovative data science platforms at the intersection of biology, behavior, and AI," says Holmes in the release. "I am particularly excited about the demand for our Ergo insights platform for life sciences, allowing scientists to aggregate a vast set of biomedical data to better inform decisions around drug development priorities." Click here to read more.

Meredith Wheeler and Maggie Segrich, co-founders of Sesh Coworking

Sesh Coworking and its founders Maggie Segrich and Meredith Wheeler are on a roll. Photo courtesy of Sesh

Sesh Coworking, described as Houston’s first female-focused and LGBTQIA+ affirming coworking, has been operating its 2808 Caroline Street location's second-floor space since January, but the first floor, as of this week, is now open to membership and visitors. The new build-out brings the location to over 20,000 square feet of space.

Called The Parlor, the new space includes additional desks, common areas, a wellness room, and a retail pop-up space. Since its inception in early 2020, Sesh has overcome the pandemic-related obstacles in its path and even seen a 60 percent increase in membership with an overall 240 percent increase in sales over the past year.

“Our growth is a testament to the ever-changing landscape of Houston’s office and retail industry after the workplace dramatically changed in 2020,” says Maggie Segrich, co-founder of Sesh Coworking, in a news release. “We are ecstatic to welcome current and prospective members to our new, inclusive space.” Click here to read more.

The duo also joined the Houston Innovators Podcast to discuss Sesh's growth. Click here to listen.

Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston

A UH professor is fighting cancer with a newly created virus that targets the bad cells and leaves the good ones alone. Photo via UH.edu

A Houston researcher is developing a cancer treatment — called oncolytic virotherapy — that can kill cancer cells while being ineffective to surrounding cells and tissue. Basically, the virus targets the bad guys by "activating an antitumor immune response made of immune cells such as natural killer (NK) cells," according to a news release from the University of Houston.

However exciting this rising OV treatment seems, the early stage development is far from perfect. Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston, is hoping his work will help improve OV treatment and make it more effective.

“We have developed a novel strategy that not only can prevent NK cells from clearing the administered oncolytic virus, but also goes one step further by guiding them to attack tumor cells. We took an entirely different approach to create this oncolytic virotherapy by deleting a region of the gene which has been shown to activate the signaling pathway that enables the virus to replicate in normal cells,” Zhang says in the release. Click here to read more.

A UH professor is fighting cancer with a newly created virus that targets the bad cells and leaves the good ones alone. Photo via Getty Images

University of Houston researchers snag $1.8M to develop cancer-fighting virus

immunotherapy innovation

Viruses attack human cells, and that's usually a bad thing — some Houston researchers have received fresh funding to develop and use the evil powers of viruses for good.

The developing cancer treatment is called oncolytic virotherapy and has risen in popularity among immunotherapy research. The viruses can kill cancer cells while being ineffective to surrounding cells and tissue. Basically, the virus targets the bad guys by "activating an antitumor immune response made of immune cells such as natural killer (NK) cells," according to a news release from the University of Houston.

Zhang, who is also a M.D. Anderson professor in the Department of Biology & Biochemistry, has received a $1.8 million grant from the National Institutes of Health to continue his work.

Zhang and his team are specifically creating a new OV — called FusOn-H2 and based on the Herpes simplex 2 virus.

“Our recent studies showed that arming FusOn-H2 with a chimeric NK engager (C-NK-E) that can engage the infiltrated natural killer cells with tumor cells could significantly enhance the effectiveness of this virotherapy,” he says. “Most importantly, we observed that tumor destruction by the joint effect of the direct oncolysis and the engaged NK cells led to a measurable elicitation of neoantigen-specific antitumor immunity.”

Shaun Zhang is the director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston and M.D. Anderson professor in the Department of Biology & Biochemistry. Image via UH.edu

The University of Houston, a Tier One research institution, has a few ongoing projects focusing on treating or preventing COVID-19. Photo courtesy of University of Houston

University of Houston researchers studying COVID-19 prevention and treatment

research roundup

Researchers across the country are focusing on all things COVID-19 — from biotherapies and treatment to vaccines and prevention. A handful of researchers based out of the University of Houston are doing their best to move the needle on a cure or reliable vaccine.

Here are three research projects currently ongoing at UH.

UH pharmacy professors take it back to basics

UH College of Pharmacy professors Gomika Udugamasooriya (left) and Bin Guo are studying how the virus enters the human body. Photo via uh.edu

When thinking about how to prevent the spread of COVID-19, two UH pharmacy professors are looking at how the virus enters the body. Then, this information can help develop protection of that entry point.

"The human entry of coronaviruses depends on first binding of the viral spike proteins to human cellular receptors that basically offer a cellular doorknob," says Gomika Udugamasooriya, associate professor of pharmacological and pharmaceutical sciences, in a press release. "The virus latches onto the specific human cellular receptor, ACE2, and sneaks inside to replicate itself within the cell to spread throughout the body."

Now, the goal of new drugs and vaccines is to protect that ACE2. Udugamasooriya is working with Bin Guo, associate professor of pharmaceutics, on this research, which is in the initial screening levels and identified drug-lead validations. They are working to apply their unique cell-screening technology to identify specific synthetic chemical drug leads called peptoids that can bind to ACE2 receptor, according to the release.

"Peptoids are easier to make, compatible with biological systems and economical to produce," says Udugamasooriya.

Duo aims to create inhalation vaccine for COVID-19

Navin Varadarajan, UH engineering professor (left), and pharmaceutics professor Xinli Liu, pharmaceutics professor, are collaborating on development and testing of a COVID-19 inhalation vaccine. Photo via uh.edu

If the disease itself is airborne, can't the vaccine be too? That's what M.D. Anderson Associate Professor of Chemical and Biomolecular Engineering Navin Varadarajan looking into.

"For airborne pathogens, the nasal mucosa is the first point of defense that needs to be breached," says Varadarajan in a news release. "Mucosal immunity and vaccines are fundamentally important for a wide range of pathogens including influenza, severe acute respiratory syndrome coronavirus (SARS-CoV) and the current SARS-CoV-2."

Varadarajan is focusing on the spike protein to protect at virus entry. These proteins are known for building strong immune responses, flexibility and scalability, and absence of infectious particles. He is working with Xinli Liu, associate professor of pharmaceutics.

"As with any vaccine, a variety of factors determine their efficacy including the antigen used for electing a response, the adjuvants and immunomodulators, the efficient delivery of the antigen to appropriate target cells, and the route of vaccination," Varadarajan says.

The man with three different vaccine options

UH Professor Shaun Zhang is in the process of developing three COVID-19 vaccine candidates for injection. Photo via uh.edu

Shaun Zhang, director for the Center for Nuclear Receptors and Cell Signaling, usually works on developing treatment or vaccines for cancer and viral infection. Now, he's switched gears to work on three different vaccine candidates for COVID-19.

"The data collected from our studies show that our vaccine candidates can generate neutralizing antibodies, which can protect cells from infection by SARS-CoV-2 when tested in vitro," says Zhang in a press release. "We are now working on further improvement for the vaccine design."

Zhang's approach is neutralizing antibody production, and he's tapped into using "subunit vaccine containing either the entire spike protein or the receptor binding portion, which helps the virus enter the target cell, and delivered either by DNA formulation or by a herpes simplex virus-based vector," according to the release. Low cost and simplicity are two priorities for Zhang's work.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas female-founded companies raised more than $1 billion in 2024, VC data shows

by the numbers

Female-founded companies in Dallas-Fort Worth may rack up more funding deals and more money than those in Houston. However, Bayou City beats DFW in one key category — but just barely.

Data from PitchBook shows that in the past 16 years, female-founded companies in DFW collected $2.7 billion across 488 deals. By comparison, female-founded companies in the Houston area picked up $1.9 billion in VC through 343 deals.

Yet if you do a little math, you find that Houston ekes out an edge over DFW in per-deal values. During the period covered by the PitchBook data, the value of each of the DFW deals averaged $5.53 million. But at $5,54 million, Houston was just $6,572 ahead of DFW for average deal value.

Not surprisingly, the Austin area clobbered Houston and DFW.

During the period covered by the PitchBook data, female-founded companies in the Austin area hauled in $7.5 billion across 1,114 deals. The average value of an Austin deal: more than $6.7 million.

Historically, funding for female-established companies has lagged behind funding for male-established companies. In 2024, female-founded companies accounted for about one-fourth of all VC deals in the U.S., according to PitchBook.

PitchBook noted that in 2024, female-founded companies raised $38.8 billion, up 27 percent from the previous year, but deal count dropped 13.1 percent, meaning more VC for fewer startups. In Texas, female-founded companies brought in $1.3 billion last year via 151 deals. The total raised is the same as 2023, when Texas female founders got $1.3 billion in capital across 190 deals.

“The VC industry is still trying to find solid footing after its peak in 2021. While some progress was made for female founders in 2024, particularly in exit activity, female founders and investors still face an uphill climb,” says Annemarie Donegan, senior research analyst at PitchBook.

Here are 3 Houston innovators to know right now

Innovators to Know

Editor's note: These Houston innovators are making big strides in the fields of neurotechnology, neurodevelopmental diagnosis, and even improving the way we rest and recharge.

For our latest roundup of Innovators to Know, we meet a researcher who is working with teams in Houston and abroad to develop an innovative brain implant; a professor who has created an AI approach to diagnosis; and a local entrepreneur whose brand is poised for major expansion in the coming years.

Jacob Robinson, CEO of Motif Neurotech

Houston startup Motif Neurotech has been selected by the United Kingdom's Advanced Research + Invention Agency (ARIA) to participate in its inaugural Precision Neurotechnologies program. The program aims to develop advanced brain-interfacing technologies for cognitive and psychiatric conditions. Three Rice labs will collaborate with Motif Neurotech to develop Brain Mesh, which is a distributed network of minimally invasive implants that can stimulate neural circuits and stream neural data in real time. The project has been awarded approximately $5.9 million.

Motif Neurotech was spun out of the Rice lab of Jacob Robinson, a professor of electrical and computer engineering and bioengineering and CEO of Motif Neurotech.

Robinson will lead the system and network integration and encapsulation efforts for Mesh Points implants. According to Rice, these implants, about the size of a grain of rice, will track and modulate brain states and be embedded in the skull through relatively low-risk surgery. Learn more.

Dr. Ryan S. Dhindsa, Dhindsa Lab

Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and his team have developed an artificial intelligence-based approach that will help doctors to identify genes tied to neurodevelopmental disorders. Their research was recently published the American Journal of Human Genetics.

Dhindsa Lab uses “human genomics, human stem cell models, and computational biology to advance precision medicine.” The diagnoses that stem from the new computational tool could include specific types of autism spectrum disorder, epilepsy and developmental delay, disorders that often don’t come with a genetic diagnosis.

“Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered,” Dhindsa says. Learn more.

Khaliah Guillory, Founder of Nap Bar

From nap research to diversity and inclusion, this entrepreneur is making Houston workers more productiveFrom opening Nap Bar and consulting corporations on diversity and inclusion to serving the city as an LGBT adviser, Khaliah Guillory is focused on productivity. Courtesy of Khaliah Guillory

Khalia Guillory launched her white-glove, eco-friendly rest sanctuary business, Nap Bar, in Houston in 2019 to offer a unique rest experience with artificial intelligence integration for working professionals, entrepreneurs and travelers who needed a place to rest, recharge and rejuvenate.

Now she is ready to take it to the next level, with a pivot to VR and plans to expand to 30 locations in three years.

Guillory says she’s now looking to scale the business by partnering with like-minded investors with experience in the wellness space. She envisions locations at national and international airports, which she says offer ripe scenarios for patrons needing to recharge. Additionally, Guillory wants to build on her initial partnership with UT Health by going onsite to curate rest experiences for patients, caregivers, faculty, staff, nurses and doctors. Colleges also offer an opportunity for growth. Learn more.

United breaks ground on $177 million facility and opens tech center at IAH

off the ground

United Airlines announced new infrastructure investments at George Bush Intercontinental Airport as part of the company’s ongoing $3.5 billion investment into IAH.

United broke ground on a new $177 million Ground Service Equipment (GSE) Maintenance Facility this week that will open in 2027.

The 140,000-square-foot GSE facility will support over 1,800 ground service vehicles and with expansive repair space, shop space and storage capacity. The GSE facility will also be targeted for LEED Silver certification. United believes this will provide more resources to assist with charging batteries, fabricating metal and monitoring electronic controls with improved infrastructure and modern workspaces.

Additionally, the company opened its new $16 million Technical Operations Training Center.

The center will include specialized areas for United's growing fleet, and advanced simulation technology that includes scenario-based engine maintenance and inspection training. By 2032, the Training Center will accept delivery of new planes. This 91,000-square-foot facility will include sheet metal and composite training shops as well.

The Training Center will also house a $6.3 million Move Team Facility, which is designed to centralize United's Super Tug operations. United’s IAH Move Team manages over 15 Super Tugs across the airfield, which assist with moving hundreds of aircraft to support flight departures, remote parking areas, and Technical Operations Hangars.

The company says it plans to introduce more than 500 new aircraft into its fleet, and increase the total number of available seats per domestic departure by nearly 30%. United also hopes to reduce carbon emissions per seat and create more unionized jobs by 2026.

"With these new facilities, Ground Service Equipment Maintenance Facility and the Technical Operations Training Center, we are enhancing our ability to maintain a world-class fleet while empowering our employees with cutting-edge tools and training,” Phil Griffith, United's Vice President of Airport Operations, said in a news release. “This investment reflects our long-term vision for Houston as a critical hub for United's operations and our commitment to sustainability, efficiency, and growth."

View All Listings